Literature DB >> 11027345

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.

D Frenkel1, O Katz, B Solomon.   

Abstract

The epitope EFRH, corresponding to amino acids 3-6 within the human beta-amyloid peptide (AbetaP), acts as a regulatory site controlling both the formation and disaggregation process of the beta-amyloid fibrils (Abeta). Locking of this epitope by highly specific antibodies affects the dynamics of the entire AbetaP molecule, preventing self-aggregation as well as enabling resolubilization of already formed aggregates. Production of such antibodies by repeated injections of toxic human Abeta fibrils into transgenic mice suggests the feasibility of vaccination against Alzheimer's disease. Here, we report the development of an immunization procedure for the production of effective anti-aggregating beta-amyloid antibodies based on filamentous phages displaying the EFRH peptide as specific and nontoxic antigen. Effective autoimmune antibodies were obtained by EFRH phage administration in guinea pigs, which exhibit AbetaP identical to the human AbetaP region. Moreover, because of the high antigenicity of the phage, no adjuvant is required to obtain high affinity anti-aggregating IgG antibodies after a short immunization period of 3 weeks. Availability of such antibodies opens up possibilities for the development of an efficient and long-lasting vaccination for the prevention and treatment of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027345      PMCID: PMC17221          DOI: 10.1073/pnas.97.21.11455

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation.

Authors:  D Frenkel; M Balass; E Katchalski-Katzir; B Solomon
Journal:  J Neuroimmunol       Date:  1999-03-01       Impact factor: 3.478

2.  Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage.

Authors:  A E Willis; R N Perham; D Wraith
Journal:  Gene       Date:  1993-06-15       Impact factor: 3.688

3.  N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies.

Authors:  D Frenkel; M Balass; B Solomon
Journal:  J Neuroimmunol       Date:  1998-08-01       Impact factor: 3.478

Review 4.  Alzheimer's disease--from cause to cure?

Authors:  G Vines
Journal:  Trends Biotechnol       Date:  1993-02       Impact factor: 19.536

Review 5.  Neuroimmune mechanisms in Alzheimer disease pathogenesis.

Authors:  P L McGeer; J Rogers; E G McGeer
Journal:  Alzheimer Dis Assoc Disord       Date:  1994       Impact factor: 2.703

6.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

7.  Beta-amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease.

Authors:  D M Araujo; C W Cotman
Journal:  Brain Res       Date:  1992-01-08       Impact factor: 3.252

8.  Oral anti-IgE immunization with epitope-displaying phage.

Authors:  A W Zuercher; S M Miescher; M Vogel; M P Rudolf; M B Stadler; B M Stadler
Journal:  Eur J Immunol       Date:  2000-01       Impact factor: 5.532

9.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

Review 10.  Role of the beta-amyloid precursor protein in Alzheimer's disease.

Authors:  F Ashall; A M Goate
Journal:  Trends Biochem Sci       Date:  1994-01       Impact factor: 13.807

View more
  50 in total

1.  EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials.

Authors:  Vered Lavie; Maria Becker; Rachel Cohen-Kupiec; Iftach Yacoby; Rela Koppel; Manuela Wedenig; Birgit Hutter-Paier; Beka Solomon
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 2.  Alzheimer's disease: strategies for disease modification.

Authors:  Martin Citron
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

3.  Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide.

Authors:  Remy Robert; Marie-Paule Lefranc; Anahit Ghochikyan; Michael G Agadjanyan; David H Cribbs; William E Van Nostrand; Kim L Wark; Olan Dolezal
Journal:  Mol Immunol       Date:  2010 Nov-Dec       Impact factor: 4.407

Review 4.  Amyloid-beta immunotherapy for Alzheimer's disease.

Authors:  H J Fu; B Liu; J L Frost; C A Lemere
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 5.  Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

6.  A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice.

Authors:  Claude Nicolau; Ruth Greferath; Teodor Silviu Balaban; Jaime E Lazarte; Robert J Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

Review 7.  Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice.

Authors:  Cynthia A Lemere; Edward T Spooner; Jodi F Leverone; Chica Mori; Melitza Iglesias; Jeanne K Bloom; Timothy J Seabrook
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

8.  Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease.

Authors:  Jan G Schiltz; Ulrich Salzer; M Hasan Mohajeri; Daniel Franke; Jochen Heinrich; Jovan Pavlovic; M Axel Wollmer; Roger M Nitsch; Karin Moelling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

Review 9.  Immunotherapy for Alzheimer's disease.

Authors:  David S Gelinas; Kevin DaSilva; Daniela Fenili; Peter St George-Hyslop; Joanne McLaurin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

10.  T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease.

Authors:  Yair Fisher; Anna Nemirovsky; Rona Baron; Alon Monsonego
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.